Broker Panmure Liberum has reiterated its buy rating on Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)’s shares with a target price of 23.3p after Scancell announced a strategic partnership with PharmaJet for the supply of the Stratis intramuscular (IM) needle-free injection system.
Scancell will use PharmaJet’s Stratis needle-free intramuscular delivery system for its SCIB1/iSCIB1+ DNA cancer vaccine.
This collaboration is aimed at ensuring a seamless transition into Phase 2/3 clinical trials, anticipated to begin in 2025.
Panmure Liberum remains optimistic about Scancell’s upcoming clinical data, expected in late 2024 and early 2025.
Given the increasing interest in cancer vaccines in recent months we expect the clinical data expected in both Q4-24 and Q1-25 to be both value enhancing and to raise the Scancell profile,” said Panmure.
“We expect this to put the company in a strong position for raising funding for a potentially pivotal clinical trial and/or out-licensing.”